ACADIA Pharmaceuticals has strengthened its position in the niche neurological pharmaceutical space through its FDA-approved products Nuplazid and Daybue, which address Parkinson’s disease psychosis and Rett syndrome respectively. After years of volatile financial performance affected by patent litigation and development setbacks, 2025 marked a return to profitability with operating income reaching $105 million and net income surging to $391 million [F1]. The company also boasts a robust liquidity profile with a current ratio above 3.8, supporting continued R&D investment and commercial expansion. However, patent infringement lawsuits against generic manufacturers remain unresolved, including upcoming trials that could affect exclusivity duration [S4][S5]. Future growth hinges on pipeline advancement such as ACP-711 for essential tremor under a licensed partnership with Saniona. Watch for updates on clinical milestones and regulatory approvals to assess trajectory [N1][N3][S28][S11].